Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

Docetaxel 2tanespimycin 1motexafin gadolinium 1cemiplimab 1alpha-2'-deoxythioguanosine 1Temozolomide 1Radiotherapy 1Radiosurgery 1Pemetrexed 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Large Cell × Temozolomide × Clear all
NCT00632203 2017-06-07

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

Merck Sharp & Dohme LLC

Phase 2 Terminated
53 enrolled 10 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡